Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing in autoimmune and related diseases, has raised $53 million in an oversubscribed equity financing. This substantial investment will fuel the continued clinical development of FB-102, a promising anti-CD122 monoclonal antibody therapeutic candidate. The financing attracted significant interest from new and existing investors, including prominent firms like OrbiMed, Janus Henderson Investors, and Tybourne Capital Management. This capital infusion strengthens Forte’s financial position, enabling the company to pursue multiple autoimmune indications for FB-102.
A study involving healthy volunteers has recently concluded, and a celiac disease trial is currently in progress, with preliminary results anticipated in the second quarter of 2025. The company also plans to explore FB-102’s potential in other autoimmune conditions within the next year. These developments position 2025 as a potentially pivotal year for FB-102’s clinical progress. Forte Biosciences will host an R&D Day on December 3rd to provide further insights into its research and development activities. Details regarding the event will be shared soon.
TD Cowen spearheaded the financing as the lead placement agent, with Guggenheim Securities providing capital markets advisory services. Chardan, Rodman & Renshaw, and Brookline Capital Markets served as co-placement managers. Forte Biosciences focuses on developing FB-102, a proprietary anti-CD122 monoclonal antibody, for various autoimmune and related diseases. The securities in this financing have not been registered under the Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or an applicable exemption. Forte Biosciences has agreed to file a registration statement with the SEC for investors’ resale of the securities.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
